Aurora Cannabis Inc.

Aurora Cannabis Inc. (ACB) Stock Analysis

$4.170

-0.117 (-2.80%)At close

Loading chart…
High
4.310
Open
4.210
VWAP
4.20
Volume
1.19M
Mkt Cap
258.02M
Low
4.130
Amount
5.02M
EV/EBITDA, TTM
-6.10

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company operates through its Cannabis segment. The Cannabis segment comprises the Canadian, Europe, Australian and New Zealand CGUs. The Company offers cannabis products including dried flower, pre-rolls, infused pre-rolls, capsules, cannabis oils, concentrates, vapes, edibles, beverages, and topicals. Its brands include Aurora, MedReleaf, Pedanios, San Raf, WMMC, Tasty's, and others. The Company is engaged in distributing wholesale medical cannabis in various international markets, including Australia and New Zealand. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., and ACB Captive Insurance Company Inc., among others.

AI analysis of Aurora Cannabis Inc. (ACB)

Buy

Aurora Cannabis Inc is a good buy right now, trading at $4.49, with a recent RSI of 69.36 indicating strong momentum. The stock has seen a 14.54% increase over the past 5 days, suggesting positive short-term momentum. Additionally, the company has a gross margin of 47.68% in its latest quarter, which is significantly higher than previous quarters, indicating improved operational efficiency. However, the main risk is the ongoing hostile takeover bid from Curaleaf, which could lead to volatility in the stock price.

Valuation Metrics

The current forward P/E ratio for Aurora Cannabis Inc. (ACB) is 109.89, compared to its 5-year average forward P/E of -47.18.

Forward P/E

Fair
5Y Average P/E
-47.18
Current P/E
109.89
Overvalued
306.85
Undervalued
-401.21

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
0.15
Current EV/EBITDA
-6.10
Overvalued
41.60
Undervalued
-41.30

Forward P/S

Fair
5Y Average P/S
1.72
Current P/S
0.86
Overvalued
3.23
Undervalued
0.21

Alphio AI Price Scenarios for ACB

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ACB

$8.45

Scenario price

B

Base

Base · 50%ACB

$7.70

Scenario price

B

Bear

Bear · 25%ACB

$6.10

Scenario price

Events Timeline

2026-10-14 (ET)

16:00:00

Aurora Cannabis Explores Alternatives to Surpass Curaleaf's Acquisition Bid

16:00:00

Aurora Cannabis Recommends Shareholders Reject Curaleaf's Acquisition Offer

2026-10-08 (ET)

07:30:00

Aurora Cannabis Completes Facility Expansion in Leuna, Germany

2026-10-06 (ET)

17:00:00

Aurora Cannabis Responds to Curaleaf's Takeover Bid

12:00:00

Curaleaf Increases Offer to Acquire Aurora to $6

News

ACB FAQ — answered by Alphio AI

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company operates through its Cannabis segment. The Cannabis segment comprises the Canadian, Europe, Australian and New Zealand CGUs. The Company offers cannabis products including dried flower, pre-rolls, infused pre-rolls, capsules, cannabis oils, concentrates, vapes, edibles, beverages, and topicals. Its brands include Aurora, MedReleaf, Pedanios, San Raf, WMMC, Tasty's, and others. The Company is engaged in distributing wholesale medical cannabis in various international markets, including Australia and New Zealand. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., and ACB Captive Insurance Company Inc., among others. It operates in the Healthcare sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).

Aurora Cannabis Inc is a good buy right now, trading at $4.49, with a recent RSI of 69.36 indicating strong momentum. The stock has seen a 14.54% increase over the past 5 days, suggesting positive short-term momentum. Additionally, the company has a gross margin of 47.68% in its latest quarter, which is significantly higher than previous quarters, indicating improved operational efficiency. However, the main risk is the ongoing hostile takeover bid from Curaleaf, which could lead to volatility in the stock price.

Community

More ↗
jadeprism9710/5/2026

$ACB Curaleaf is offering about 1.5x sales for this struggling cannabis company. Take the money and shift into the better stock.

Show more
Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started